Stock ANAB ANAPTYSBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
18.87 USD -2.08% Intraday chart for AnaptysBio, Inc. -4.84% -11.90%
Apr. 16 Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target MT
Apr. 11 Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target MT

Business Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Number of employees: 117

Sales per Business

USD in Million2022Weight2023Weight Delta
GSK - Royalty
100.0 %
5 51.4 % 17 100.0 % +224.51%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Australia
100.0 %
10 100.0 % 17 100.0 % +66.78%

Managers

Managers TitleAgeSince
Daniel Faga CEO
 Chief Executive Officer 44 21-11-25
Dennis Mulroy DFI
 Director of Finance/CFO 69 20-07-14
Paul Lizzul CTO
 Chief Tech/Sci/R&D Officer 49 20-07-30
Nick Montemarano IRC
 Investor Relations Contact - -
Priya Raina PRN
 Corporate Officer/Principal - 22-06-30
Ben Stone PRN
 Corporate Officer/Principal - 21-12-31
Martin Dahl PRN
 Corporate Officer/Principal - 17-12-31
Beth Mueller HRO
 Human Resources Officer - 19-09-30
David McKeon AUD
 Comptroller/Controller/Auditor 52 17-03-31
Lewis Gryziewicz LAW
 General Counsel - 18-12-31

Members of the board

Members of the board TitleAgeSince
Hollings Renton BRD
 Director/Board Member 77 15-06-29
Dennis Fenton BRD
 Director/Board Member 72 18-03-04
Magda Marquet BRD
 Director/Board Member 65 21-01-17
Oleg Nodelman BRD
 Director/Board Member 47 21-04-07
John Schmid BRD
 Director/Board Member 60 15-06-29
John Orwin CHM
 Chairman 59 23-09-14
J. Ware BRD
 Director/Board Member 71 17-08-23
Daniel Faga CEO
 Chief Executive Officer 44 21-11-25
Rita Jain BRD
 Director/Board Member 62 23-04-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,763,081 26,656,090 ( 99.60 %) 0 99.60 %

Shareholders

NameEquities%Valuation
EcoR1 Capital, LLC
28.10 %
7,521,024 28.10 % 169 M $
Deep Track Capital LP
7.611 %
2,036,990 7.611 % 46 M $
Tang Capital Management LLC
7.288 %
1,950,609 7.288 % 44 M $
BlackRock Advisors LLC
6.144 %
1,644,362 6.144 % 37 M $
Vanguard Fiduciary Trust Co.
5.157 %
1,380,115 5.157 % 31 M $
Boxer Capital LLC
4.857 %
1,300,000 4.857 % 29 M $
First Light Asset Management LLC
4.623 %
1,237,178 4.623 % 28 M $
Woodline Partners LP
4.465 %
1,194,974 4.465 % 27 M $
Jeffrey Robert Jay
3.650 %
976,981 3.650 % 22 M $
Frazier Life Sciences Management LP
3.362 %
899,700 3.362 % 20 M $

Company contact information

AnaptysBio, Inc.

10770 Wateridge Circle Suite 210

92121-5801, San Diego

+858 362 6295

http://www.anaptysbio.com
address AnaptysBio, Inc.(ANAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Ratings for AnaptysBio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
19.27 USD
Average target price
43.5 USD
Spread / Average Target
+125.74%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANAPTYSBIO, INC. Stock AnaptysBio, Inc.
-10.04% 516M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+0.67% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-10.26% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANAB Stock
  4. Company AnaptysBio, Inc.